Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient
First published: 01 June 2010
No abstract is available for this article.
References
- 1
Valent P,
Akin C,
Escribano L,
Födinger M,
Hartmann K,
Brockow K
et al.
Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.
Eur J Clin Invest
2007; 37: 435–453.
- 2
Carter M,
Robyn J,
Bressler P,
Walker J,
Shapiro G,
Metcalfe D.
Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.
J Allergy Clin Immunol
2007; 119: 1550–1551.
- 3
Kontou-Fili K.
High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.
Allergy
2008; 63: 376–378.
- 4
Beck LA,
Marcotte GV,
MacGlashan D,
Togias A,
Saini S.
Omalizumab-induced reductions in mast cell Fc Epsilon RI expression and function.
J Allergy Clin Immunol
2004; 114: 527–530.
- 5
Drew AC,
Eusebius NP,
Kenins L,
De Silva HR,
Suphioglu C,
Rolland JM
et al.
Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human lymphocyte reactivity.
J Immunol
2004; 173: 5872–5879.
- 6
Nopp A,
Johannson SG,
Ankerst J,
Bylin G,
Cordell LO,
Grönneberg R
et al.
Basophil allergen threshold sensitivity: a useful approach to anti-IgE treatment efficacy evaluation.
Allergy
2006; 61: 298–302.
